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Regulatory T cells and IL-10 in allergic inﬂammation
 
Catherine M. Hawrylowicz
 
Recent studies suggest that human regulatory T (T reg) cells protect against 
the development of allergic and asthmatic disease and that their function is 
impaired during active disease. Two new studies contribute to our 
understanding of the role that T reg cells play in the control of allergic airway 
disease in mice. However, these studies also highlight several outstanding 
questions in the field.
 
Human disease versus animal models
 
Human allergic airway disease is a
complex condition characterized by in-
creased amounts of systemic IgE, ele-
vated allergen-specific T helper (Th)2
cells and their products, airway hyperre-
activity (AHR), and structural changes
in the lung. Animal models of both
acute and chronic allergic airway re-
sponses have been described, although
none of these models captures all aspects
of human disease (1). Nonetheless, ani-
mal  models have provided invaluable
insights into the molecular mechanisms
of allergic airway disease, including the
role of Th2 cytokines in disease pathol-
ogy and, more recently, the role of regu-
latory pathways in the control of disease.
These models thus provide an important
preclinical tool for dissecting the bio-
logical mechanisms involved in the sen-
sitization  to allergens and the effector
mechanisms associated with disease, as
well as for the investigation of novel
therapies for human disease.
 
Regulatory T cells
 
T reg cells control peripheral immune
responses and are likely to play a cen-
tral role in determining the incidence
and severity of several immune patholo-
gies, including autoimmune, infectious,
allergic, and asthmatic diseases (2).
One eventual hope for the treatment
of allergic airway disease, as for other
immune-mediated pathologies, is to
design therapies that boost endogenous
allergen-specific T reg cell function or
that induce de novo T reg cell activity.
Long-term, allergen-specific relief from
disease symptoms provided by T reg
cells would likely be preferable to the
nonspecific, noncurative regimens that
are currently prescribed.
There are two major categories of T
reg cells described to date. The first is
the naturally occurring, thymically de-
rived CD4
 
 
 
CD25
 
 
 
 T reg cells that
express high levels of the transcription
factor Foxp3, which is essential for their
development and function (3–6). The
other category is the antigen-specific T
reg cells, which can be induced in vitro
and in vivo under particular conditions
of antigenic stimulation. These antigen-
specific T reg cells secrete antiinflamma-
tory cytokines such as interleukin (IL)-10
and/or TGF
 
 
 
, and regulate immune
responses and inflammatory pathologies
(2, 7). Induced T reg cells that secrete
IL-10 are often referred to as IL-10–T
reg cells, or Tr1 cells; those that secrete
TGF
 
 
 
 have been referred to as Th3 cells.
However, it is likely that both categories
of T reg cells require one or both of
these cytokines to evoke their suppressive
functions during different stages or types
of inflammatory responses. Many ques-
tions remain to be answered regarding
the distinct roles of these T reg cell
subsets during immune responses. Still
unknown, for example, is whether these
cells exhibit complementary functions,
regulate each other’s activity, or use
common inhibitory mechanisms.
 
T reg cells in health and disease
 
Recent studies have suggested that natu-
rally occurring T reg cells and antigen-
induced IL-10–producing T reg cells
have a physiological role in protecting
against human allergic disease. A rare
mutation in the gene encoding FOXP3
results in a disease called IPEX (im-
munedysregulation, polyendocrinopathy
and enteropathy, X-linked) syndrome.
Individuals with IPEX syndrome suffer
from a range of autoimmune endocrine
pathologies as well as allergic symptoms
including severe eczema, increased serum
IgE levels, eosinophilia, and food allergies
(6, 8). Peripheral blood mononuclear
cells (PBMCs) from atopic or allergic
patients generally proliferate more exten-
sively and produce more Th2 cytokines
in response to allergen stimulation than
PBMCs from nonatopic control subjects.
When CD25
 
 
 
 T cells were depleted
from PBMC cultures derived from the
control subjects in these studies, these
responses were significantly enhanced
(9, 10). Collectively, these studies sug-
gest that active T reg cell–mediated
suppression of allergen-specific immune
responses occurs in healthy individuals.
Additional evidence for a physio-
logical role for IL-10–producing T reg
cells in suppressing allergic inflammation
comes from several recent studies. The
suppressive cytokine IL-10 inhibits the
activation of many cell types and effector
functions that are associated with allergic
disease (for review see reference 2). A
recent study by Akdis et al. showed that
the frequency of allergen-specific, IL-10–
secreting T cells was significantly in-
creased in nonatopic individuals com-
pared with allergic patients, whereas the
reverse was true for T cells producing the
Th2 cytokine IL-4 (11). Several other
studies similarly suggested that IL-10
levels were inversely correlated with the
severity of human disease (12–14). Fi-
nally, therapies shown to be beneficial
for the treatment of allergy and asthma,
such as allergen immunotherapy or glu-
cocorticoid therapy, have been shown
to increase IL-10 synthesis by T cells
(15–17). Whether the IL-10 is pro-
duced by T reg cells, activated effector
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T cells, and/or non–T cells is likely to
vary in different experimental and clini-
cal systems, and the predominant cellu-
lar source may even vary at different
times during the course of an immune
response. Nevertheless, these studies
suggest a central role for IL-10 in disease
control.
 
T reg cells and control of allergic airway 
disease in mice
 
Two studies in this issue clarify the role
of CD4
 
 
 
CD25
 
 
 
 T reg cells in the regu-
lation of allergic responses and show
several similarities to observations made
in humans. The study by Lewkowich et
al. (p. 1549) investigates the impact of
depleting CD4
 
 
 
CD25
 
 
 
 T reg cells on
sensitization to allergens in susceptible
and resistant strains of immunocompe-
tent mice (18). The study by Kearley et
al. (p. 1539) examines the effect of
adoptively transferring CD4
 
 
 
CD25
 
 
 
 T
reg cells into allergen-sensitized mice
before antigen challenge (19).
As both articles point out, these are
not the first reports to show that natu-
rally occurring CD4
 
 
 
CD25
 
 
 
 T reg cells
can control allergic airway disease.
However, none of the earlier studies
used wild-type, immunocompetent ani-
mals nor did they use as direct an exper-
imental approach; overall the results of
past studies have been conflicting. For
example, in one of the earliest studies to
deplete CD4
 
 
 
CD25
 
 
 
 T cells in allergic
airway disease, the removal of these cells
paradoxically ameliorated inflammation
and AHR. These data are difficult to in-
terpret but could potentially reflect the
depletion of CD4
 
 
 
CD25
 
 
 
 effector T
cells in addition to the T reg cells (20),
as effector T cells up-regulate CD25
upon activation (5). Using a more in-
direct approach, another recent study
showed that transfer of ovalbumin-spe-
cific CD4
 
 
 
 T cells that were depleted of
CD25
 
 
 
 cells induced more airway in-
flammation upon transfer than did the
nondepleted population. However, in
the same study CD4
 
 
 
CD25
 
 
 
 T reg cells
that were expanded in vitro before
transfer exhibited no regulatory activity
in vivo (21). This result either calls into
question the ability of these cells to
ameliorate disease or suggests that in
vitro expansion in some way altered
their suppressive capacity. In a model
of chronic airway inflammation, CD4
 
 
 
CD25
 
 
 
 T cells infiltrated the lung and
inhibited airway inflammation but had
no effect on AHR (22). Finally, using a
transgenic model of hyper-IgE responses,
Curotto et al. showed that both CD4
 
 
 
CD25
 
 
 
 and CD4
 
 
 
CD25
 
 
 
 T cells in-
hibited the development of IgE re-
sponses and Th2 differentiation (23). Al-
though the likely consensus from these
past studies is that CD4
 
 
 
CD25
 
 
 
 T reg
cells can prevent allergic airway inflam-
mation, both the mechanism of inhibi-
tion and effects on other aspects of dis-
ease were unresolved.
In their new study, Lewkowich et
al. examined the capacity of CD4
 
 
 
CD25
 
 
 
 T reg cells to act before allergic
sensitization to control the develop-
ment of allergic airway disease. They
used an anti-CD25 antibody to deplete
CD25
 
 
 
 cells in vivo and showed that
the treatment greatly diminished the
number of lung-infiltrating CD4
 
 
 
 T
cells that express high levels of the
CD25 antigen, but did not change the
number of T cells expressing interme-
diate levels of CD25. Depletion of
CD25
 
 
 
 cells before delivery of a house
dust mite allergen led to significantly
increased Th2 cytokine responses, IgE
levels, eosinophilia, and AHR in al-
lergy-resistant mice (C3H strain), but
had comparatively little effect in the al-
lergy-sensitive mice (A/J strain). The
authors observed no difference in the
ex vivo regulatory activity of CD25
 
 
 
 T
reg cells from the sensitive or resis-
tant mouse strains nor in the suscepti-
bility of effector T cells to regulation.
These data led them to attribute the
observed differences between the sensi-
tive and resistant mice to a non–T cell
population.
The non–T cell population in
question appeared to be a subset of
dendritic cells (DCs). CD25
 
 
 
 cell de-
pletion resulted in a greater frequency
of immunogenic pulmonary myeloid
DCs in the lungs of the resistant mice,
and these DCs expressed elevated levels
of MHC class II, and the costimulatory
molecules CD80 and CD86. When
cultured with T cells, the DCs trig-
gered enhanced production of Th2 cy-
tokines (such as IL-4, IL-5, and IL-13)
from the T cells. The authors explained
this phenomenon by showing that de-
pletion of CD25
 
 
 
 cells resulted in re-
duced production of the Th1-inducing
cytokine IL-12p40 by the myeloid
DCs. Interestingly, the frequency of
another type of pulmonary DC—plas-
macytoid DCs—although present at a
considerably lower frequency than my-
eloid DCs, appeared to be reduced by
CD25
 
 
 
 cell depletion.
Lewkowich et al. went on to dem-
onstrate that although depletion of
CD4
 
 
 
CD25
 
 
 
 T reg cells before sensi-
tization resulted in significant increases
in AHR, depletion of pulmonary
CD25
 
 
 
 T reg cells during the effector
phase of the immune response did not
enhance AHR. One potential caveat in
this study is that although the number
of lung CD4
 
 
 
 T cells expressing inter-
mediate levels of the CD25 antigen was
unaltered by the CD25 antibody treat-
ment, it is still possible that subtle alter-
ations in the effector CD4
 
 
 
 T cell
or CD4
 
 
 
CD25
 
 
 
 cell populations oc-
curred. A unique and interesting aspect
of the study by Lewkowich et al. is the
use of an animal that is relatively resis-
tant to allergic sensitization, which ar-
guably parallels the human situation
more closely than many other models.
 
The IL-10 question
 
Using a complementary approach—
adoptive transfer of CD4
 
 
 
CD25
 
 
 
 T reg
cells—Kearley et al. explored the capacity
of purified antigen-specific CD4
 
 
 
CD25
 
 
 
T reg cells to inhibit disease when ad-
ministered before challenge of immuno-
competent mice with an antigen (ovalbu-
min) to which the mice had previously
been sensitized. In this study, transfer of
T reg cells inhibited AHR, eosinophil re-
cruitment, and Th2 cytokine production.
The T reg cell–mediated inhibition was
dependent on the production of IL-10, as
blocking the IL-10 receptor in vivo
reversed the inhibition. However,
CD4
 
 
 
CD25
 
 
 
 T reg cells derived from
IL-10–deficient mice were still able to
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suppress allergic inflammation, implying
that the IL-10 need not be produced by
the T reg cells themselves. Indeed, the
authors found that IL-10 was produced
by host T cells in the lung.
The study by Kearley et al. high-
lights a major unresolved issue in the
field of CD4
 
 
 
CD25
 
 
 
 T reg cell biol-
ogy, namely how these cells act in
vivo. Although naturally occurring T
reg cells are proposed to act via cell
contact–dependent mechanisms in vi-
tro, they have been proposed to work
variously through inhibitory cytokines
or non–cytokine-dependent mecha-
nisms in vivo, depending on the model
being studied (5). Additional complex-
ity arises from the fact that Th2 cells
are reportedly less sensitive than Th1
cells to regulation by CD4
 
 
 
CD25
 
 
 
 T
reg cells (24).
Kearley et al. suggest that IL-10
production by host T cells is required
for suppression; the study by Lewkow-
ich did not formally investigate whether
IL-10 was required for suppression in
their system. Surprisingly, Kearley et al.
did not observe increased IL-10 pro-
duction by lung macrophages or DC
populations, as might perhaps have
been predicted by an earlier indepen-
dent study (25). However, this disparity
might simply reflect the different sys-
tems used and the different time points
at which the response was analyzed. In
the earlier study, the investigators sug-
gested that induction of T cell tolerance
after respiratory exposure to high doses
of allergen inhibited the development
of AHR, and showed that pulmonary
DCs synthesized IL-10 and promoted
the induction of IL-10–producing T
reg cells (Fig. 1). The reasons why the
initial source of IL-10 differed in the
two reports will be of considerable in-
terest to determine in future studies.
Notably, parallels exist between the
Kearley et al. study and an in vitro study
in which human CD4
 
 
 
CD25
 
 
 
 cells
were shown to induce an IL-10–depen-
dent regulatory phenotype in CD4
 
 
 
CD25
 
 
 
 T cells (26). Indeed, most stud-
ies suggest that CD4
 
 
 
CD25
 
 
 
 T reg cells
are not major producers of IL-10. How-
ever, it may be possible to boost their
capacity for IL-10 production, albeit to
a lesser extent than in CD4
 
 
 
 T cells not
enriched for CD25
 
 
 
 cells (2). It will be
of interest for future studies in both
mice and humans to resolve which T
cell–derived or non–T cell–derived
sources of IL-10 are critical for mediat-
ing disease protection or resolution.
 
Control of T reg cell function in disease
 
Studies using PBMCs from humans
demonstrate that allergen-specific Th2
cells from allergic patients who exhibit
strong in vitro responses to allergen, and
patients with active hay fever, are less
sensitive to inhibition by CD4
 
 
 
CD25
 
 
 
T reg cells. (10, 27). If loss of inhibitory
function is associated with more active
disease, one prediction is that the loss of
T reg cell activity will be most apparent
at the disease site. Although I am un-
aware of studies that directly address this
question in human allergy or asthma,
studies of autoimmune pathologies have
analyzed tissue-derived CD4
 
 
 
CD25
 
 
 
 T
reg cell function. One report showed that
CD25
 
 
 
 T reg cells isolated from the joint
synovium of rheumatoid arthritis patients
were functional when removed from
their inflammatory environment. In that
study, environmental signals in the in-
flamed joint, in this case IL-7 and IL-15,
exerted a negative effect on T reg cell
function that likely prevented them from
suppressing inflammation in vivo (28).
Pasare and Medzhitov previously
demonstrated that IL-6, produced by
activated DCs, impaired the regulatory
activity of CD4
 
 
 
CD25
 
 
 
 T reg cells
(29) (Fig. 1). However, other studies
suggest that IL-6 may also play a role
in controlling regulatory functions in
allergic disease. Indeed, this cytokine
is increased in patients with allergic
asthma (30). Furthermore, cross-link-
ing of CD40 on human respiratory
tract DCs enhances their IL-6 produc-
tion (31). A study by Doganci et al.
Figure. 1. Control of allergic airway disease by regulatory T cells. Allergic airway disease is 
caused by inappropriate Th2-driven immune responses to “harmless” antigens, or allergens, in the 
environment. CD4 CD25  and IL-10–producing T reg cells can regulate allergic sensitization in vivo 
through inhibitory effects on Th2 cells or on dendritic cells (DCs) in the lung. T reg cells can also 
induce the production of the immunosuppressive cytokine IL-10 by host lung T cells (not shown). In 
turn, DCs can produce immunomodulatory cytokines such as IL-6, which has been shown to inhibit 
CD4 CD25   T reg cell function, and IL-10, which has been shown to induce IL-10–producing T reg cells.
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published earlier this year suggested a
role for naturally occurring T reg cells
and IL-6 in controlling allergic airway
disease in mice (32). This study con-
firmed earlier work supporting a role
for IL-6 in promotion of Th2 responses
(33), and showed that blocking IL-6
leads to local expansion of Foxp3
 
 
 
CD4
 
 
 
CD25
 
 
 
 T reg cells in the lung
that have an increased suppressive ca-
pacity. Thus, IL-6 and IL-10 emerge as
two cytokines with the potential to
contribute to CD4
 
 
 
CD25
 
 
 
 T reg cell
activity in disease (Fig. 1).
 
The future
 
Although mouse models are imperfect,
they are needed to further dissect T
reg cell function in allergic airway dis-
ease and to facilitate comparisons with
emerging data from human studies.
Evidence exists for a role for CD4
 
 
 
CD25
 
 
 
 T reg cells in limiting allergic
sensitization, airway inflammation, and
even AHR if delivered before allergen
challenge. However, critical questions
remain that will be most readily ad-
dressed in murine models. These in-
clude whether CD4
 
 
 
CD25
 
 
 
 T reg and
IL-10–producing T reg cells can act in
a therapeutic context once disease is al-
ready established (for example, to reverse
structural remodelling of the airways),
which critical mechanisms are involved,
and which local signals regulate the
regulator cells. Clearly, further studies
will be required to fully elucidate the rel-
ative importance of and the relationship
between CD25
 
 
 
 T reg cells and IL-10–
producing T reg cells in controlling
Th2-mediated allergic inflammation.
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